Skip to main content
SpringerLink
Log in

Cytokine Activation of Natural Killer Cells

  • Protocol
  • First Online:
Cancer Vaccines

Part of the book series: Methods in Molecular Biology ((MIMB,volume 1139))

Abstract

CD3−CD56+ natural killer (NK) cells can kill various tumors in a non major histocompatibility complex (MHC)-restricted fashion. Recent advances have been made in the application of NK cells for the treatment of patients with acute myelogenous leukemia (AML). Allogeneic donor-derived NK cells can be activated in vitro and infused into patients receiving stem cell transplants. We describe in this chapter the method to activate NK cells with cytokines and to ascertain their degree of activation.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Protocol
USD 49.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Farag SS, Caligiuri MA (2006) Human natural killer cell development and biology. Blood Rev 20:123–137

    Article  CAS  PubMed  Google Scholar 

  2. Lin SJ, Kuo ML (2011) Cytotoxic function of umbilical cord blood natural killer cells: relevance to adoptive immunotherapy. Pediatr Hematol Oncol 28:640–646

    Article  CAS  PubMed  Google Scholar 

  3. Suck G (2006) Novel approaches using natural killer cells in cancer therapy. Semin Cancer Biol 16:412–418

    Article  CAS  PubMed  Google Scholar 

  4. McKenna DH et al (2007) Good manufacturing practices production of natural killer cells for immunotherapy: a six-year single-institution experience. Transfusion 47:520–528

    Article  CAS  PubMed  Google Scholar 

  5. Rosenberg SA et al (1989) Experience with the use of high-dose interleukin-2 in the treatment of 652 cancer patients. Ann Surg 210:474–484

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  6. Grabstein KH et al (1994) Cloning of a T cell growth factor that interacts with the beta chain of the interleukin-2 receptor. Science 264:965–968

    Article  CAS  PubMed  Google Scholar 

  7. Lin SJ et al (2008) Role of interleukin-15 in umbilical cord blood transplantation. Int Rev Immunol 27:518–531

    Article  CAS  PubMed  Google Scholar 

  8. Munger W et al (1995) Studies evaluating the antitumor activity and toxicity of interleukin-15, a new T cell growth factor: comparison with interleukin-2. Cell Immunol 165:289–293

    Article  CAS  PubMed  Google Scholar 

  9. Lin SJ, Kuo ML (2008) Effect of cyclosporin-A on interleukin-15 activated umbilical cord blood natural killer cell function. Cytotherapy 10:397–405

    Article  CAS  PubMed  Google Scholar 

  10. Alpdogan O, Eng JM et al (2005) Interleukin-15 enhances immune reconstitution after allogeneic bone marrow transplantation. Blood 105:865–873

    Article  CAS  PubMed  Google Scholar 

  11. Timonen T, Saksela E (1980) Isolation of human NK cells by density gradient centrifugation. J Immunol Methods 36:285–289

    Article  CAS  PubMed  Google Scholar 

  12. Boyum A (1968) Isolation of mononuclear cells and granulocytes form human blood. Scand J Clin Lab Invest 21(s97):77–89

    CAS  Google Scholar 

  13. Boyum A (1976) Isolation of lymphocytes, granulocytes and macrophages. Scand J Immunol 5(s5):9–15

    Article  PubMed  Google Scholar 

  14. Melder RJ et al (1991) Adhesion characteristics of human interleukin-2-actviated natural killer cells. Cell Immunol 132:177–192

    Article  CAS  PubMed  Google Scholar 

  15. Whiteside TL (1997) Isolation of human NK cells and generation of LAK activity. Curr Protoc Immunol 2:Unit 7.7

    Google Scholar 

  16. Grimm EA et al (1982) Lymphokine-activated killer cell phenomenon. Lysis of natural killer-resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes. J Exp Med 155: 1823–1841

    Article  CAS  PubMed  Google Scholar 

  17. Whiteside TL (1997) Measurement of cytotoxic activity of NK/LAK cells. Curr Protoc Immunol 2:Unit 7.18

    Google Scholar 

  18. Lin SJ et al (2000) Effect of interleukin-15 and Flt3-ligand on natural killer cell expansion and activation: umbilical cord vs. adult peripheral blood mononuclear cells. Pediatr Allergy Immunol 11:168–174

    CAS  PubMed  Google Scholar 

  19. Oner O, Savasan S (2005) Combinational IL-2/IL-15 induction dose not future enhance IL-15-induced lymphokine-activated killer cell cytotoxicity against human leukemia/lymphoma cells. Clin Immunol 115:240–249

    Article  Google Scholar 

  20. Lin SJ et al (2004) Evaluation of cytotoxic function and apoptosis in interleukin (IL)-12/IL-15-treatedumbilical cord or adult peripheral blood natural killer cells by a propidium-iodide based flow cytometry. Pediatr Allergy Immunol 15:79–85

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Asthma, Allergy, and Rheumatology, Department of Pediatrics, Chang Gung Memorial Hospital, Kweishan, Taoyuan, Taiwan

    Syh-Jae Lin & Pei-Tzu Lee

  2. Department of Microbiology and Immunology, Graduate Institute of Biomedical Science, Chang Gung University, Kweishan, Taoyan, Taiwan

    Ming-Ling Kuo

Authors
  1. Syh-Jae Lin
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Pei-Tzu Lee
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ming-Ling Kuo
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Morphogenesis, Inc., Tampa, Florida, USA

    Michael J.P. Lawman

  2. Morphogenesis, Inc., Tampa, Florida, USA

    Patricia D. Lawman

Rights and permissions

Reprints and permissions

Copyright information

© 2014 Springer Science+Business Media New York

About this protocol

Cite this protocol

Lin, SJ., Lee, PT., Kuo, ML. (2014). Cytokine Activation of Natural Killer Cells. In: Lawman, M., Lawman, P. (eds) Cancer Vaccines. Methods in Molecular Biology, vol 1139. Humana Press, New York, NY. https://doi.org/10.1007/978-1-4939-0345-0_19

Download citation

  • DOI: https://doi.org/10.1007/978-1-4939-0345-0_19

  • Published:

  • Publisher Name: Humana Press, New York, NY

  • Print ISBN: 978-1-4939-0344-3

  • Online ISBN: 978-1-4939-0345-0

  • eBook Packages: Springer Protocols

Publish with us

Policies and ethics

Search

Navigation